CYTK · Insider trading · 13F holders · Congress trades
Cytokinetics Inc (CYTK)
Who is buying and selling CYTK: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 54
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $11.8M
- Congress trades, 12 months
- 3
CYTK at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 5 CYTK insiders filed 14 sales worth $11.8M on SEC Form 4, and no open-market purchases; 14 of the sales were pre-planned under Rule 10b5-1.
- 54 13F filers hold CYTK among their 50 largest positions, worth $3.8B combined, including Behzad Aghazadeh and Mark Kingdon. The biggest bets by portfolio weight are Sarissa Capital Management LP (10.9%), Melqart Asset Management (UK) Ltd (6.2%) and Integral Health Asset Management, LLC (5.6%). In their latest 13Fs, 4 managers opened a new position and 14 added to one.
- Members of Congress have disclosed 5 CYTK trades since 2025, 3 purchases and 0 sales in the past year; the latest was Gilbert Ray Cisneros, Jr. (D-CA), buying $1K–15K on Sep 29, 2026.
- CYTK last closed at $63.31 on Oct 29, 2026.
CYTK insider trading
Between Aug 1, 2026 and Oct 29, 2026, 5 CYTK insiders filed 14 sales worth $11.8M on SEC Form 4, and no open-market purchases; 14 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Oct 20, 2026 | Malik Fady Ibraham | EVP Research & Development | Sale10b5-1 | 3,500 | $64.01 | $224K | SEC |
| Oct 13, 2026 | Blum Robert I | President & CEO, Director | Sale10b5-1 | 7,500 | $62.88 | $472K | SEC |
| Oct 6, 2026 | Malik Fady Ibraham | EVP Research & Development | Sale10b5-1 | 3,500 | $61.38 | $215K | SEC |
| Sep 28, 2026 | Blum Robert I | President & CEO, Director | Sale10b5-1 | 7,500 | $65.46 | $491K | SEC |
| Sep 22, 2026 | Malik Fady Ibraham | EVP Research & Development | Sale10b5-1 | 3,500 | $68.29 | $239K | SEC |
| Sep 15, 2026 | Blum Robert I | President & CEO, Director | Sale10b5-1 | 105,426 | $69.62 | $7.3M | SEC |
| Sep 15, 2026 | Landry Robert E | Director | Sale10b5-1 | 1,000 | $72.13 | $72K | SEC |
| Sep 11, 2026 | Landry Robert E | Director | Sale10b5-1 | 1,000 | $74.66 | $75K | SEC |
| Sep 8, 2026 | Malik Fady Ibraham | EVP Research & Development | Sale10b5-1 | 3,500 | $75.46 | $264K | SEC |
| Sep 1, 2026 | Parshall B Lynne | Director | Sale10b5-1 | 5,000 | $71.48 | $357K | SEC |
| Aug 31, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sale10b5-1 | 10,000 | $70.24 | $702K | SEC |
| Aug 31, 2026 | Blum Robert I | President & CEO, Director | Sale10b5-1 | 7,500 | $70.24 | $527K | SEC |
| Aug 18, 2026 | Malik Fady Ibraham | EVP Research & Development | Sale10b5-1 | 3,500 | $75.82 | $265K | SEC |
| Aug 10, 2026 | Blum Robert I | President & CEO, Director | Sale10b5-1 | 7,500 | $76.76 | $576K | SEC |
Who owns CYTK? Hedge funds and superinvestors
54 13F filers hold CYTK among their 50 largest positions, worth $3.8B combined, including Behzad Aghazadeh and Mark Kingdon. The biggest bets by portfolio weight are Sarissa Capital Management LP (10.9%), Melqart Asset Management (UK) Ltd (6.2%) and Integral Health Asset Management, LLC (5.6%). In their latest 13Fs, 4 managers opened a new position and 14 added to one.
Superinvestors holding CYTK: Behzad Aghazadeh 3.8% · Mark Kingdon 1.8%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc.Mutual fund manager | 1.0% | $1.6B | 18,718,498 | +6.8% shares | Q2 2026 |
| Behzad AghazadehHedge fund | 3.8% | $425.9M | 4,999,999 | +50.0% shares | Q2 2026 |
| Rtw Investments, LPHedge fund | 2.1% | $243.8M | 2,862,003 | +5.2% shares | Q2 2026 |
| Polar Capital Holdings PlcHedge fund | 0.5% | $192.0M | 2,253,649 | — | Q2 2026 |
| Integral Health Asset Management, LLCHedge fund | 5.6% | $136.3M | 1,600,000 | +0.0% shares | Q2 2026 |
| Armistice Capital, LLCHedge fund | 2.8% | $102.3M | 1,201,342 | +57.1% shares | Q2 2026 |
| Frazier Life Sciences Management, L.P.Hedge fund | 2.2% | $98.8M | 1,159,879 | +0.0% shares | Q2 2026 |
| GW&K Investment Management, LLCWealth manager | 0.6% | $78.0M | 916,107 | — | Q2 2026 |
| Melqart Asset Management (UK) LtdHedge fund | 6.2% | $65.4M | 767,525 | -9.1% shares | Q2 2026 |
| Siren, L.L.C.Investment manager | 1.3% | $64.7M | 758,952 | +23.6% shares | Q2 2026 |
| Foresite Capital Management IV, LLCHedge fund | 21.0% | $60.9M | 714,695 | +42.0% shares | Q2 2026 |
| Deep Track Capital, LPHedge fund | 0.9% | $59.6M | 700,000 | -49.1% shares | Q2 2026 |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.Investment manager | 3.1% | $56.3M | 660,310 | +0.0% shares | Q2 2026 |
| Affinity Asset Advisors, LLCHedge fund | 2.3% | $46.9M | 550,000 | -21.5% shares | Q2 2026 |
| First Turn Management, LLCInstitutional asset manager | 4.8% | $44.9M | 527,412 | +85.9% shares | Q2 2026 |
| Checkpoint Capital L.P.Hedge fund | 10.4% | $40.5M | 475,000 | +163.9% shares | Q2 2026 |
| Emerald Advisers, LLCInstitutional asset manager | 0.9% | $39.0M | 457,956 | — | Q2 2026 |
| ADAR1 Capital Management, LLCHedge fund | 1.8% | $39.0M | 457,907 | -27.6% shares | Q2 2026 |
| GSK plcCorporation | 4.8% | $29.0M | 340,434 | +0.0% shares | Q2 2026 |
| Trails Edge Capital Partners, LPHedge fund | 3.9% | $24.5M | 288,089 | -4.0% shares | Q2 2026 |
| Emerald Mutual Fund Advisers TrustMutual fund manager | 0.8% | $23.8M | 279,769 | — | Q2 2026 |
| Polaris Capital Management, LLCMutual fund manager | 2.4% | $22.8M | 346,100 | +29.7% shares | Q3 2026 |
| E. Ohman J:or Asset Management ABAsset manager | 0.5% | $20.1M | 305,255 | +0.2% shares | Q3 2026 |
| Sarissa Capital Management LPHedge fund | 10.9% | $19.5M | 228,623 | +0.0% shares | Q2 2026 |
| Sphera Funds Management Ltd.Hedge fund | 2.7% | $18.7M | 219,987 | — | Q2 2026 |
| Nicholas Investment Partners, LPInvestment manager | 1.1% | $17.8M | 209,071 | — | Q2 2026 |
| Tri Locum Partners LPHedge fund | 2.0% | $16.5M | 194,000 | New | Q2 2026 |
| PFM Health Sciences, LPHedge fund | 1.4% | $16.3M | 191,686 | — | Q2 2026 |
| Rock Springs Capital Management LPHedge fund | 0.8% | $16.0M | 187,980 | — | Q2 2026 |
| DAFNA Capital Management LLCHedge fund | 2.8% | $14.7M | 171,998 | -20.9% shares | Q2 2026 |
The 30 largest of 54 positions, by value. Each manager counts with its latest 13F (Q3 2026: 3, Q2 2026: 51). Screen CYTK in the grand portfolio →
CYTK stock trades by members of Congress
Members of Congress have disclosed 5 CYTK trades since 2025, 3 purchases and 0 sales in the past year; the latest was Gilbert Ray Cisneros, Jr. (D-CA), buying $1K–15K on Sep 29, 2026.
| Filed | Member | Trade | Amount | Traded | Since |
|---|---|---|---|---|---|
| Oct 12, 2026 | Gilbert Ray Cisneros, Jr.D-CA · House | Buy | $1K–15K | Sep 29, 2026 | -4.1% |
| Jul 2, 2026 | Gilbert Ray Cisneros, Jr.D-CA · House | Buy | $1K–15K | Jun 30, 2026 | -26.1% |
| Nov 18, 2025 | Gilbert Ray Cisneros, Jr.D-CA · House | Buy | $1K–15K | Oct 9, 2025 | +4.4% |
| Aug 13, 2025 | Lisa C. McClainR-MI · House | Sale | $1K–15K | Jun 17, 2025 | +93.5% |
| Aug 13, 2025 | Lisa C. McClainR-MI · House | Buy | $1K–15K | Jun 11, 2025 | +90.2% |
2 members have traded CYTK: Gilbert Ray Cisneros, Jr., Lisa C. McClain.
Analysis mentioning CYTK
Posts from the blog that cover Cytokinetics Inc, newest first.
CYTK questions and answers
Are insiders buying CYTK stock?
Between Aug 1, 2026 and Oct 29, 2026, 5 CYTK insiders filed 14 sales worth $11.8M on SEC Form 4, and no open-market purchases; 14 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own CYTK?
54 13F filers hold CYTK among their 50 largest positions, worth $3.8B combined, including Behzad Aghazadeh and Mark Kingdon. The biggest bets by portfolio weight are Sarissa Capital Management LP (10.9%), Melqart Asset Management (UK) Ltd (6.2%) and Integral Health Asset Management, LLC (5.6%). In their latest 13Fs, 4 managers opened a new position and 14 added to one.
Has Congress traded CYTK?
Members of Congress have disclosed 5 CYTK trades since 2025, 3 purchases and 0 sales in the past year; the latest was Gilbert Ray Cisneros, Jr. (D-CA), buying $1K–15K on Sep 29, 2026.
Who is the largest holder of CYTK?
Among 13F filers, T. Rowe Price Investment Management, Inc. reports the largest CYTK position, $1.6B (18,718,498 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Sarissa Capital Management LP's: 10.9% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.